Arkolith/Insider Trading/PTHS/Form 4

Ligand Pharmaceuticals Inc

Director, 10% OwnerPelthos Therapeutics Inc. (PTHS) · full profile →Form 4 · filed Dec 19, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
0 non-derivative · 2 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 17, 2025Disposed to issuer(D)0——0
Dec 17, 2025Grant(A)0———

Transaction Codes

D
Disposition to the issuer
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-25-326891) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML